natalizumab
Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 458283255
- Drug.type
- mab
- Drug.image
- Natalizumab 4IRZ.png
- Drug.caption
- Natalizumab Fab fragment bound to the headpiece of an α4-integrin. From PDB .
- Drug.mab_type
- mab
- Drug.source
- zu/o
- Drug.target
- alpha-4 integrin
- Drug.tradename
- Tysabri, others
- Drug.MedlinePlus
- a605006
- Drug.DailyMedID
- Natalizumab
- Drug.pregnancy_AU
Article
12 sectionsContents
- Medical uses
- Adverse effects
- Mechanism of action
- Multiple sclerosis
- Crohn's disease
- Interactions
- History
- Society and culture
- Legal status
- Biosimilars
- References
- Further reading
Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier.
Natalizumab is a monoclonal antibody which targets a protein called α4β1 integrin on white blood cells involved in inflammation. By attaching to integrin, natalizumab is thought to stop white blood cells from entering the brain and spinal cord tissue, thereby reducing inflammation and the resulting nerve damage.